STOCK TITAN

Lixte Biotechnology Holdings, Inc. - $LIXT STOCK NEWS

Welcome to our dedicated page for Lixte Biotechnology Holdings news (Ticker: $LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lixte Biotechnology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lixte Biotechnology Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.62%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
Lixte Biotechnology Holdings, Inc.

Nasdaq:LIXT

LIXT Rankings

LIXT Stock Data

6.50M
1.98M
20.48%
5.08%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EAST SETAUKET

About LIXT

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in